Roche (ROG) PT Set at CHF 300 by Jefferies Group
Roche (VTX:ROG) has been assigned a CHF 300 price target by equities researchers at Jefferies Group in a research report issued on Friday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Jefferies Group’s target price suggests a potential upside of 19.07% from the company’s current price.
Several other equities analysts also recently commented on the stock. JPMorgan Chase & Co. set a CHF 300 price objective on shares of Roche and gave the company a “buy” rating in a research note on Thursday. Barclays set a CHF 305 price objective on shares of Roche and gave the company a “buy” rating in a research note on Tuesday. Nord/LB reissued a “buy” rating on shares of Roche in a research note on Tuesday. Goldman Sachs Group set a CHF 325 price objective on shares of Roche and gave the company a “buy” rating in a research note on Wednesday, December 13th. Finally, Deutsche Bank set a CHF 264 price objective on shares of Roche and gave the company a “neutral” rating in a research note on Tuesday, December 12th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. Roche presently has an average rating of “Hold” and an average target price of CHF 263.42.
Shares of Roche (VTX:ROG) opened at CHF 251.95 on Friday. Roche has a twelve month low of CHF 226.10 and a twelve month high of CHF 273. The firm has a market cap of $217,190.00 and a P/E ratio of 22.40.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.